Back to announcements list
Quarterly Update
RNS Number : 2010Q
RTW Venture Fund Limited
26 October 2021
 

LEI: 549300Q7EXQQH6KF7Z84

26 October 2021

RTW Venture Fund Limited

Quarterly Update

RTW Venture Fund Limited (the "Company") is pleased to announce the Fact Sheet for the quarter ended 30 September 2021 is now available on the Company's website in the Document Library Section www.rtwfunds.com/venture-fund.

For Further Information

RTW Investments, LP                                                              +1 (646) 597 6980
Stephanie Sirota, Chief Business Officer

Alexandra Taracanova, PhD, Director of Investor Relations

Julia Enright, Senior Business Development Associate

 

Elysium Fund Management Limited                                     +44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

 

J.P. Morgan Cazenove                                                              +44 (0)20 7742 4000

William Simmonds

Jérémie Birnbaum

James Bouverat (Sales)

 

Barclays                                                                             +44 (0)20 7623 2323

Tom Swerling

Andrew Tusa

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund Limited invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCDZMZGLKVGMZM